United States Food and Drug Administration
"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
| Descriptor ID |
D014486
|
| MeSH Number(s) |
I01.409.418.750.600.650.760 N03.540.348.500.500.600.650.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".
Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".
This graph shows the total number of publications written about "United States Food and Drug Administration" by people in this website by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 4 | 4 |
| 2009 | 1 | 5 | 6 |
| 2010 | 0 | 6 | 6 |
| 2011 | 1 | 11 | 12 |
| 2012 | 1 | 5 | 6 |
| 2013 | 2 | 4 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 3 | 4 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 10 | 12 |
| 2019 | 2 | 4 | 6 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 5 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.
-
Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis? BMJ Open. 2024 Dec 20; 14(12):e085210.
-
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
-
Mitigation of errors on an FDA-approved platform for cytomegalovirus viral load assay. J Clin Microbiol. 2024 Jul 16; 62(7):e0041624.
-
How Aggregate Safety Assessment Planning Supports Investigational New Drug Safety Reporting Decisions. Ther Innov Regul Sci. 2024 Jul; 58(4):579-590.
-
Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 Feb 08; 116(2):177-179.
-
Aggregate IND Safety Reporting for Smaller Companies and Programs. Ther Innov Regul Sci. 2024 03; 58(2):368-379.
-
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 11 01; 9(11):1489-1490.
-
Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval. J Ocul Pharmacol Ther. 2023 10; 39(8):572-582.
-
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023 10; 129(9):1389-1396.
-
Serving on the FDA oncologic drugs advisory committee. Clin Adv Hematol Oncol. 2022 11; 20(11):649-651.